EVO
Evotec SE
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · DE
$1.42
+2.90%Year over year
Reported trailing growth
- Revenue
- -7.4%
- EBITDA
- -4.7%
- EBIT
- -90.8%
- EPS
- -30.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -5.7%
- EBITDA
- +187.9%
- EPS
- +78.9%
Three-year CAGR
- Revenue
- +0.3%
- EBITDA
- +82.8%
- EBIT
- +5.1%
- Net income
- +49.3%
- EPS
- +50.0%
- Free cash flow
- +30.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026